Canbex Therapeutics
Rreating spasticity in multiple sclerosis (MS) and other disorders..
Launch date
Employees
Market cap
-
Enterprise valuation
€8—13m (Dealroom.co estimates Apr 2013.)
Company register number 05073720
London England (HQ)
Financials
Estimates*
| EUR | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | - | - |
| % growth | (5 %) | 4 % | 561 % | (92 %) | (93 %) | - | - |
| EBITDA | (<1m) | (<1m) | (1.3m) | (2.6m) | (3.0m) | (3.8m) | (<1m) |
| % EBITDA margin | (619 %) | (584 %) | (142 %) | (3581 %) | (60818 %) | - | - |
| Profit | (<1m) | (<1m) | (1.1m) | (2.0m) | (2.6m) | (3.2m) | (<1m) |
| % profit margin | (673 %) | (457 %) | (120 %) | (2725 %) | (53072 %) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| N/A | £1.8m | Early VC | |
$2.3m | Series A | ||
| N/A | £1.3m | Grant | |
N/A | Acquisition | ||
| Total Funding | €5.8m | ||
Related Content
Recent News about Canbex Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.